BHST BIOHARVEST SCIENCES INC.
Price Chart
Executive Summary
BioHarvest Sciences announced a $1.2 million Stage 2 CDMO contract for developing a rare fragrance compound using its Botanical Synthesis platform, following a successful Stage 1 in March 2026. The contract, from a UAE-based investment group, includes 20% ownership of developed compositions and a manufacturing royalty, with production targeted for H2 2027. While the contract validates the platform, the revenue impact is small relative to the $84M market cap and commercialization is years away.
Actionable Insight
The contract is a positive technology validation but has minimal near-term financial impact. Monitor progress toward Stage 3 and commercial trials for signs of broader adoption. The stock may see modest positive momentum on the news, but given historical underperformance of BHST following similar announcements, any pop could be short-lived.
Key Facts
- Signed $1.2M Stage 2 CDMO contract for rare fragrance development
- Stage 1 completed March 2026; Stage 2 expected to take 6-9 months
- BioHarvest retains 20% ownership of compositions and manufacturing royalty rights
- Commercial production targeted for second half of 2027
- Premium fragrance market estimated at $23B globally
Financial Impact
$1.2 million contract revenue with additional royalty potential, but near-term financial impact limited
Risk Factors
- No assurance of commercialization or achieving production timelines
- Single contract with undisclosed counterparty; limited diversification
- Long timeline to revenue (H2 2027) with execution risk
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001723464-26-000022 |
| Document: bhsc_ex991.htm | 0001723464-26-000022 |
| Document: 0001723464-26-000022-index-headers.html | 0001723464-26-000022 |
| Document: 0001723464-26-000022-index.html | 0001723464-26-000022 |
| Document: 0001723464-26-000022.txt | 0001723464-26-000022 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
17d ago
|
6-K
| $3.90 $3.56 | ▼ −8.72% | ▼ −8.67% | $3.20 (−17.95%) |
|
May 14, 2026
4w ago
|
6-K
| $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $3.20 (−23.08%) |
|
May 14, 2026
4w ago
|
6-K
| $4.16 $3.82 | ▲ +8.17% | ▲ +7.46% | $3.20 (+23.08%) |
|
May 14, 2026
4w ago
|
6-K
| $4.16 $3.82 | ▼ −8.17% | ▼ −7.46% | $3.20 (−23.08%) |
|
May 12, 2026
4w ago
|
6-K
| $3.84 $3.96 | ▲ +3.13% | ▲ +3.05% | $3.20 (−16.67%) |
|
May 11, 2026
4w ago
|
6-K
| $3.84 $3.96 | ▲ +3.13% | ▲ +3.05% | $3.20 (−16.67%) |
|
Apr 29, 2026
6w ago
|
6-K
| $4.25 $4.21 | ▼ −0.94% | ▼ −4.05% | $3.20 (−24.71%) |
|
Mar 27, 2026
11w ago
|
6-K
| $4.32 $4.36 | ▲ +0.93% | ▼ −2.94% | $3.20 (−25.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access